Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study.

Objective: Different formulations of botulinum toxin type A (BoNTA) are not identical and may behave differently in clinical practice. The reportedly lower incidence of adverse effects with one formulation (from Allergan, Ltd.) relative to another (from Ipsen, Ltd.